Group items tagged

A new report from the Association of the British Pharmaceutical Industry (ABPI) has highlighted that while the NHS has made significant progress in the introduction of cell and gene therapies, the health service must "do more to get ready for the arrival of the advanced therapies of the future." The ABPI noted that advanced therapies, also known as Advanced Therapy Medicinal Products (ATMPs), offer hope for diseases previously deemed "untreatable." ATMPs have already been introduced for treating some rarer conditions, including haemophilia, spinal muscular atrophy, and a rare disease that causes blindness. "In some cases, these therapies can transform people's lives with just a single treatment," the Association said. The ABPI's report, titled Unlocking Access to Future ATMPs in the UK: Comparing International Approaches, emphasises the need for the NHS to revise its payment strategies for upcoming therapies.

The NHS is going to roll out a revolutionary 30-minute treatment for advanced womb cancer for women across England. The drug, called Dostarlimab, would benefit around 100 women with advanced and often incurable endometrial cancer every year after the NHS agreed early access to the treatment through the Cancer Drugs Fund. It works by attaching to a specific protein on the surface of the cancer cells, helping the immune system to detect and attack it. The treatment takes just 30 minutes to administer through the blood stream every three weeks over a 12-week period. The move is in line with the NHS Long Term Plan which aims to provide the latest cutting-edge treatments and therapies for patients.

Many people with advanced Parkinson's disease are currently required to take more than 20 pills a day to manage their symptoms, while some necessitate treatment through a permanent feeding tube. Soon, patients will only be required to wear a portable kit to get a continuous dose of the medication delivered into their bloodstream 24 hours a day. This innovative treatment, called Produodopa, will now be made available on the NHS, providing benefit to nearly 1,000 people with advanced Parkinson's disease, according to a BBC report. James Palmer, NHS England's medical director for specialised services, told the publication that the drug's rollout will offer "a vital new option on the NHS for those who aren't suitable for other treatments such as deep brain stimulation." He added that the new therapy will help patients manage their symptoms "more effectively" and improve their quality of life.

Good news for patients whose epilepsy cannot be controlled by standard anti-seizure drugs! Next month, NHS England will introduce a cutting-edge laser beam therapy that can prevent seizures in these individuals. Known as Laser Interstitial Thermal Therapy (LITT), the advanced treatment targets the part of the brain causing seizures without the need for invasive surgery, the health service said. The new fibre optic laser therapy is being offered at King's College Hospital in London and The Walton Centre in Liverpool. Starting from June, it will be gradually extended to eligible patients across England. Each year, it is expected to benefit up to 50 epilepsy patients in England who are resistant to standard anti-seizure medications. "This groundbreaking new treatment will change the lives of those with severe epilepsy improving quality of life and providing much-needed assurance," said Andrew Stephenson, Minister of State for Health.

The new Smoking Cessation Service (SCS) will commence on March 10, 2022, allowing community pharmacy contractors to register to provide the service on the NHS Business Services Authority's (NHSBSA) Manage Your Service (MYS) portal from March 1, 2022. This is the second of the two new Advanced services to be introduced this financial year, after the Hypertension case-finding service, which were agreed outcomes from negotiations for Year 3 of the Community Pharmacy Contractual Framework. Since the service is an Advanced service, contractors are free to decide if they wish to provide it, as most would be busy completing work for the Pharmacy Quality Scheme 2021/22 alongside winter-related workload, the Pharmaceutical Services Negotiating Committee said. Therefore, those who decide to start this service should consider the likelihood of receiving sufficient referrals to make provision of the service worthwhile, the PSNC said.